Scientists test double hunger blocker for obesity
NCT ID NCT07171723
Summary
This study aims to understand how the body's hunger signals work when a person is already taking a medication like semaglutide for weight loss. Researchers will give 24 participants with obesity an infusion that temporarily blocks a key hunger hormone (ghrelin) or a placebo, while they continue their regular semaglutide treatment. The goal is to see if blocking this second hunger pathway further affects food intake and metabolism, which could inform future combination treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY & OVERWEIGHT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Center for Clinical Metabolic Research, Gentofte Hospital
RECRUITINGHellerup, 2900, Denmark
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.